Close

Anti-FKBP5 DNA-encoded mAb (DMAb), pVAX1 (DMAb-1010-CQ)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-FKBP5 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • FKBP5
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

  • Entrez Gene ID
  • 2289
Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-1010-CQ CBXF-1228 Rabbit IgG
DMAb-1011-CQ Hi51B Mouse IgG Synthetic peptide corresponding to the residues of human FKBP51
DMAb-1012-CQ CBXF-0716 Mouse IgG2b, κ
DMAb-1013-CQ CBXF-1973 Mouse IgG1 Mouse FKBP51 aa. 4-199
DMAb-1014-CQ CBXF-3534 Mouse IgG1
DMAb-1015-CQ CBXF-2240 Rabbit IgG Protein corresponding to Human FKBP5 (aa 298-447)
DMAb-1016-CQ CBXF-2241 Rabbit IgG Peptide corresponding to Human FKBP5 (aa 298-447)
DMAb-1017-CQ CBXF-2064 Rabbit IgG
DMAb-1018-CQ CBXF-2645 Rat IgG2b E. coli-derived recombinant human FKBP51, Met1-Val457, Accession # Q13451
DMAb-1019-CQ CBXF-0715 Mouse IgG1, κ FKBP5 (AAH42605, 1 a.a.-457 a.a) full-length recombinant protein with GST tag
DMAb-1020-CQ CBXF-3053 Mouse IgG2b, κ Full length recombinant corresponding to aa1-457 from human FKBP5 (AAH42605) with GST tag
DMAb-1021-CQ CBXF-3054 Mouse IgG FKBP5 (AAH42605, 1aa-457aa) full-length recombinant protein with GST tag
DMAb-1022-CQ CBXF-3347 Mouse IgG Full length his-tagged human recombinant FKBP51

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-FKBP5 DNA-encoded mAb (DMAb), pVAX1 (DMAb-1010-CQ). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.